How common are gi issues with darolutamide use?

Darolutamide GI Side Effects in Clinical Trials

Darolutamide, used for non-metastatic castration-resistant prostate cancer, shows low rates of gastrointestinal (GI) issues in key trials. In the ARAMIS trial (2,719 patients), common GI effects included:

- Nausea: 9.8% (vs. 8.6% placebo)[1]
- Diarrhea: 9.1% (vs. 8.7% placebo)[2]
- Constipation: 8.6% (vs. 7.9% placebo)[1]

These were mostly grade 1-2 (mild to moderate) and led to discontinuation in under 1% of cases. Serious GI events like GI hemorrhage occurred in 1.2% (vs. 1.3% placebo), showing no clear drug link[3].

How Do Rates Compare to Other Androgen Receptor Inhibitors?

Darolutamide has fewer GI issues than enzalutamide (diarrhea 21%, nausea 12%) or apalutamide (diarrhea 20%, nausea 15%), likely due to lower brain penetration reducing overall toxicity[4][5].

| Drug | Diarrhea % | Nausea % | Discontinuation due to GI % |
|------|------------|----------|-----------------------------|
| Darolutamide (ARAMIS) | 9 | 10 | <1 |
| Enzalutamide (PROSPER) | 21 | 12 | 3 |
| Apalutamide (SPARTAN) | 20 | 15 | 2 |

What Drives GI Issues and Risk Factors?

GI effects often stem from darolutamide's anti-androgen action slowing gut motility, worsened by age >75, combo therapy with docetaxel, or pre-existing conditions like IBS. Real-world data from 2023 studies report similar rates (8-12% for diarrhea/nausea), with onset in first 3 months[6].

Patient Management Tips

Most resolve with dose adjustment or antiemetics like ondansetron. Monitor hydration; severe cases (grade 3+) are rare (<2%). Consult prescribing info for full profile[1].

[1]: Darolutamide Prescribing Information (Nubeqa)
[2]: ARAMIS Trial (NEJM 2019)
[3]: FDA Label Safety Data
[4]: Enzalutamide PROSPER Trial (JCO 2019)
[5]: Apalutamide SPARTAN Trial (NEJM 2018)
[6]: Real-World Evidence Review (Prostate Cancer Prostatic Dis 2023)